FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944335326> ?p ?o ?g. }

• W2944335326 endingPage "566" @default.
• W2944335326 startingPage "549" @default.
• W2944335326 abstract "Akathisia is a common and distressing movement disorder that can be associated with the use of antipsychotics. It is characterized by a subjective (inner restlessness) and an objective (excessive movements) component. Akathisia can have a negative impact on clinical outcome and even lead to treatment discontinuation. Although medication-induced akathisia is more commonly associated with the use of first-generation antipsychotics (FGAs), it also occurs with second-generation antipsychotics (SGAs), including the newly approved antipsychotics (NAPs) asenapine, lurasidone, iloperidone, cariprazine, and brexpiprazole. Until now, no meta-analysis has been published on the risk of akathisia for all NAPs, as monotherapy or adjunctive treatment, in patients with a severe mental illness. The primary objectives of this systematic review and meta-analysis were to (i) compare akathisia incidence rates of the NAPs, as monotherapy or adjunctive treatment, in adult patients with a severe mental illness (i.e., schizophrenia, bipolar disorder, or major depressive disorder), using data from published and unpublished randomized controlled trials; and (ii) examine the role of several study characteristics explaining differences in akathisia incidence rates between studies. A systematic literature search, using the PubMed, EMBASE, and Cochrane Library databases (until October 2018), was conducted for English-language placebo- as well as active-controlled clinical trials, including subjective (percentage of patients reporting akathisia) and/or scale-defined medication-induced akathisia incidence rates with NAPs (as monotherapy or as adjunctive treatment) in adult patients with schizophrenia, bipolar disorder, or major depressive disorder. Additional unpublished clinical trials were identified through the ClinicalTrials.gov electronic database. Two meta-analyses (incidence rates and odds ratio [OR] [placebo vs. active] of medication-induced akathisia with NAPs) were performed to obtain an optimal estimation of akathisia risks of adult patients with a severe mental illness under these treatment conditions and to assess the role of study characteristics. Two hundred and thirteen reports were selected as potentially eligible for our meta-analysis. Of these, 48 met the inclusion criteria. Eight records, identified through the ClinicalTrials.gov database and cross-referencing, and which fulfilled the inclusion criteria, were added, resulting in a total of 56 records (iloperidone = 5, asenapine = 11, lurasidone = 15, brexpiprazole = 13, cariprazine = 12). The estimated weighted mean incidence rate of akathisia was 7.7% (95% confidence interval [CI] 6.5–9.1), with estimates being 3.9% (95% CI 2.4–6.3) for iloperidone, 6.8% (95% CI 5.1–9.0) for asenapine, 10.0% (95% CI 7.4–13.5) for brexpiprazole, 12.7% (95% CI 10.1–16.1) for lurasidone, and 17.2% (95% CI 13.4–22.1) for cariprazine. After Tukey-adjustment for multiple testing, the incidence rate of akathisia was significantly (p < 0.05) lower for iloperidone than for brexpiprazole, lurasidone, and cariprazine. In addition, the incidence rate of akathisia was significantly (p < 0.05) lower for asenapine than for lurasidone and cariprazine. Finally, the incidence rate of akathisia was significantly (p < 0.05) lower for brexpiprazole than for cariprazine. Type of medication (p < 0.0001), diagnosis (p = 0.02), and race (p = 0.0003) significantly explained part of the heterogeneity of the incidence estimates of akathisia between studies. The estimated weighted OR of akathisia under medication, compared with placebo, was 2.43 (95% CI 1.91–3.10). The OR was smallest for iloperidone (OR 1.20; 95% CI 0.42–3.45) and increased for brexpiprazole (OR 2.04; 95% CI 1.09–3.83), asenapine (OR 2.37; 95% CI 1.32–4.27), lurasidone (OR 3.74; 95% CI 2.32–6.02), and cariprazine (OR 4.35; 95% CI 2.80–6.75). Only type of medication (p = 0.03) explained systematic differences in the OR for akathisia between placebo versus active treatment across studies. After Tukey-adjustment for multiple testing, no significant differences between these ORs were found. The severity of akathisia with NAPs generally is mild to moderate, only leading to treatment discontinuation in a minority of cases (< 5%). The use of a NAP raises the akathisia risk more than two-fold when compared with patients receiving placebo. Although distinctions between the different NAPs were not clear in placebo-controlled trials, the results of our meta-analyses and systematic review generally indicate that these differences more than likely reflect real differences, with iloperidone showing the most and cariprazine showing the least benign akathisia profile. Moreover, due to patient characteristics and methodological issues, incidence rates of akathisia with NAPs found in this meta-analysis may even be an underestimation of true incidence rates." @default.
• W2944335326 created "2019-05-16" @default.
• W2944335326 creator A5035769308 @default.
• W2944335326 creator A5040561724 @default.
• W2944335326 creator A5068078315 @default.
• W2944335326 creator A5080920214 @default.
• W2944335326 date "2019-05-07" @default.
• W2944335326 modified "2023-10-04" @default.
• W2944335326 title "Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis" @default.
• W2944335326 cites W1589172325 @default.
• W2944335326 cites W1868790909 @default.
• W2944335326 cites W1963580478 @default.
• W2944335326 cites W1965287457 @default.
• W2944335326 cites W1966483710 @default.
• W2944335326 cites W1967358491 @default.
• W2944335326 cites W1973117280 @default.
• W2944335326 cites W1973852234 @default.
• W2944335326 cites W1974205791 @default.
• W2944335326 cites W1974541005 @default.
• W2944335326 cites W1974599939 @default.
• W2944335326 cites W1975175152 @default.
• W2944335326 cites W1979797229 @default.
• W2944335326 cites W1981740077 @default.
• W2944335326 cites W1987935555 @default.
• W2944335326 cites W1990121386 @default.
• W2944335326 cites W1991916074 @default.
• W2944335326 cites W1997910708 @default.
• W2944335326 cites W1998023765 @default.
• W2944335326 cites W1999544522 @default.
• W2944335326 cites W2000406055 @default.
• W2944335326 cites W2002278536 @default.
• W2944335326 cites W2006478810 @default.
• W2944335326 cites W2008810498 @default.
• W2944335326 cites W2011297026 @default.
• W2944335326 cites W2011541112 @default.
• W2944335326 cites W2012183345 @default.
• W2944335326 cites W2018014668 @default.
• W2944335326 cites W2024016083 @default.
• W2944335326 cites W2024410002 @default.
• W2944335326 cites W2026802141 @default.
• W2944335326 cites W2032446177 @default.
• W2944335326 cites W2037081441 @default.
• W2944335326 cites W2039013951 @default.
• W2944335326 cites W2039404912 @default.
• W2944335326 cites W2042749834 @default.
• W2944335326 cites W2043246282 @default.
• W2944335326 cites W2044865119 @default.
• W2944335326 cites W2048731347 @default.
• W2944335326 cites W2049838937 @default.
• W2944335326 cites W2050370233 @default.
• W2944335326 cites W2054318560 @default.
• W2944335326 cites W207016966 @default.
• W2944335326 cites W2070454612 @default.
• W2944335326 cites W2075229477 @default.
• W2944335326 cites W2077487559 @default.
• W2944335326 cites W2078053761 @default.
• W2944335326 cites W2083517887 @default.
• W2944335326 cites W2084024459 @default.
• W2944335326 cites W2087727211 @default.
• W2944335326 cites W2088489501 @default.
• W2944335326 cites W2092264845 @default.
• W2944335326 cites W2094802480 @default.
• W2944335326 cites W2095530968 @default.
• W2944335326 cites W2097129122 @default.
• W2944335326 cites W2100557888 @default.
• W2944335326 cites W2101228291 @default.
• W2944335326 cites W2107950329 @default.
• W2944335326 cites W2111561440 @default.
• W2944335326 cites W2113560690 @default.
• W2944335326 cites W2118142600 @default.
• W2944335326 cites W2120893202 @default.
• W2944335326 cites W2124201657 @default.
• W2944335326 cites W2128120675 @default.
• W2944335326 cites W2133026967 @default.
• W2944335326 cites W2134476370 @default.
• W2944335326 cites W2135166041 @default.
• W2944335326 cites W2136998407 @default.
• W2944335326 cites W2140209868 @default.
• W2944335326 cites W2140725933 @default.
• W2944335326 cites W2141788833 @default.
• W2944335326 cites W2144295927 @default.
• W2944335326 cites W2145619691 @default.
• W2944335326 cites W2149950019 @default.
• W2944335326 cites W2152186040 @default.
• W2944335326 cites W2156918201 @default.
• W2944335326 cites W2163368530 @default.
• W2944335326 cites W2166033924 @default.
• W2944335326 cites W2166607892 @default.
• W2944335326 cites W2167404903 @default.
• W2944335326 cites W2167696061 @default.
• W2944335326 cites W2167715051 @default.
• W2944335326 cites W2173862535 @default.
• W2944335326 cites W2181503375 @default.
• W2944335326 cites W2191178969 @default.
• W2944335326 cites W2202043731 @default.
• W2944335326 cites W2202381266 @default.
• W2944335326 cites W2249246431 @default.
• W2944335326 cites W2259786097 @default.

• next